Evidence map›Paper›PMID 39684253›Full record

ArticleInternational journal of molecular sciences2024

Alaa Muqbil Alsirhani, Amal S Abu-Almakarem, Maha Abdullah Alwaili, Salwa Aljohani, Ibtisam Alali, Aljazi Abdullah AlRashidi, Najlaa Yousef Abuzinadah, Sahar Abdulrahman Alkhodair, Maysa A Mobasher, Tahiyat Alothaim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alaa Muqbil AlsirhaniDepartment of Chemistry, College of Science, Jouf University, Sakaka 72341, Saudi Arabia.
Amal S Abu-AlmakaremDepartment of Basic Medical Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al Baha 65431, Saudi Arabia.
Maha Abdullah AlwailiDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia.
Salwa AljohaniChemistry Department, Faculty of Science, Taibah University, Yanbu Branch, Yanbu 46423, Saudi Arabia.
Ibtisam AlaliDepartment of Chemistry, College of Science, Jouf University, Sakaka 72341, Saudi Arabia.ORCID 0009-0001-5989-8308
Aljazi Abdullah AlRashidiChemistry Department, Faculty of Science, University of Ha'il, Ha'il 81451, Saudi Arabia.
Najlaa Yousef AbuzinadahDepartment of Biological Science, College of Science, University of Jeddah, Jeddah 23714, Saudi Arabia.
Sahar Abdulrahman AlkhodairDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Maysa A MobasherDepartment of Pathology, Biochemistry Division, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0003-2987-0387
Tahiyat AlothaimDepartment of Biology, College of Science, Qassim University, Buraydah 51452, Saudi Arabia.
Thamir M EidDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-9513-8202
Karim Samy El-SaidBiochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta 31527, Egypt.ORCID 0000-0003-1511-6033

Funding

Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2024R227)
6 · The paper itself

Abstract

Doxorubicin (DOX), an anticancer drug, is used to treat several types of tumors, but it has detrimental side effects that restrict its therapeutic efficacy. One is the iron-dependent form of ferroptosis, which is characterized by elevated ROS production and iron overload.

Indexed as

Chemical and Drug Induced Liver InjuryDoxorubicinPlant ExtractsRats, Sprague-DawleySyzygiumAnimalsAntioxidantsFerroptosisLiverMaleMolecular Docking SimulationNF-E2-Related Factor 2Oxidative StressRatsAntioxidantsDoxorubicinNF-E2-Related Factor 2Plant ExtractsantioxidantsdoxorubicinferroptosishepatotoxicitySyzygium aromaticum

Identifiers

PMID39684253
PMCPMC11641798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.